Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.250 | GeneticVariation | disease | BEFREE | The data suggest an association between the beta1AR Arg389Gly polymorphism and LVH, particularly the septal hypertrophy. | 20731869 | 2010 | ||||
|
0.250 | GeneticVariation | disease | LHGDN | Our findings show that the Arg389Gly polymorphism of the ADRB1 gene confers higher risk of left ventricular hypertrophy in human essential hypertension. | 18298953 | 2008 | ||||
|
0.250 | GeneticVariation | disease | BEFREE | Our findings show that the Arg389Gly polymorphism of the ADRB1 gene confers higher risk of left ventricular hypertrophy in human essential hypertension. | 18298953 | 2008 | ||||
|
0.250 | Biomarker | disease | RGD | Specific beta1-adrenergic receptor silencing with small interfering RNA lowers high blood pressure and improves cardiac function in myocardial ischemia. | 17143192 | 2007 | ||||
|
0.250 | GeneticVariation | disease | BEFREE | Patients with mild to moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind fashion to treatment with either the angiotensin II type 1 receptor antagonist irbesartan (n = 48) or the beta(1)-adrenergic receptor blocker atenolol (n = 49) as monotherapy. | 14700505 | 2004 | ||||
|
0.250 | GeneticVariation | disease | BEFREE | One hundred and two patients with essential hypertension and left ventricular hypertrophy were allocated randomly to groups to receive double-blind treatment with either irbesartan (n = 49) or the beta(1)-adrenergic receptor blocker, atenolol ( n= 53). | 12359989 | 2002 | ||||
|
0.250 | GeneticVariation | disease | BEFREE | Patients with essential hypertension and echocardiographically diagnosed LVH were included in a double-blind study to receive treatment with either the angiotensin II type 1 receptor (AT1-receptor) antagonist irbesartan (n = 41), or the beta-1 adrenergic receptor blocker atenolol (n = 43) as monotherapy for 3 months. | 11910301 | 2002 |